LIC decreases stake in Aurobindo Pharma
Life Insurance Corporation of India has decreased its shareholding in equity shares of Aurobindo Pharma Ltd. from 2,93,55,635 to 1,31,57,165 i.e., 5.01% to 2.265% of the paid-up capital of the said Company.
"There is a net decrease of 2.745 percent in holding during the period from 25.11.2021 to 12.09.2024,"LIC stated in a BSE filing.
Medical Dialogues team had earlier reported that the new injectable facility of Eugia Steriles Private Limited , a 100% subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of the Aurobindo Pharma, situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, had received its first product approval from the US Food and Drug Administration (US FDA) for Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL).
Read also: Aurobindo Pharma step-down arm AP facility gets product approval from USFDA
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.
The company has 29 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
